Help us: Donate
Follow us on:

Alerity Therapeutics

Organization Description

Part of the Life Biosciences group of companies, Alterity is developing first-in-class therapies to treat neurodegenerative disease. Their lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.


David Sinclair, Ph.D.

Harvard Medical School - Professor of Genetics